By Fineline Cube 
China-based Harbour BioMed (HKG: 2142) has entered into a global strategic collaboration with Japan-headquartered Otsuka Pharmaceutical Co., Ltd. The partnership aims to jointly advance the development of HBM7020, a BCMAxCD3 bispecific T-cell engager for the treatment of autoimmune diseases.
Collaboration Details
Under the agreement, Otsuka Pharma will obtain an exclusive license to develop, manufacture, and commercialize HBM7020 in all regions outside Greater China (excluding mainland China, Hong Kong, Macau, and Taiwan). Harbour BioMed will receive an upfront payment of USD 47 million, along with near-term milestone payments.
Financial Terms
Harbour BioMed is eligible for up to USD 623 million in further payments upon achieving specific R&D and commercial milestones. Additionally, tiered royalties based on future net sales will be provided.
Future Collaboration
Building on this partnership, the two companies will explore future collaboration opportunities in the field of T-cell engagers.
Drug Development
HBM7020 is a BCMAxCD3 bispecific antibody (BsAb) developed using Harbour BioMed’s fully human HBICE bispecific antibody technology and Harbour Mice platform. The antibody works by targeting BCMA on cell surfaces and CD3 on T cells, effectively bridging target cells with T cells to activate T-cell-mediated killing.-Fineline Info & Tech